FDA Declines to Approve Summit's Lung Cancer Drug
The agency issued a complete response letter for ivonescimab, citing an overall survival result that was not statistically significant.
Updated on Nov. 15, 2026 in Cancer

The U.S. Food and Drug Administration declined to approve ivonescimab, a lung cancer drug from Summit Therapeutics, in a complete response letter dated November 15, 2026. The drug is intended for patients whose cancer progressed after earlier therapies.
Why it matters
The decision means the drug cannot be marketed in the United States for now, even though it significantly delayed disease progression in a late-stage trial. Regulators weighed overall survival, a key measure of long-term benefit, which did not reach statistical significance.
The late-stage trial met its progression-free survival endpoint but did not show a statistically significant overall survival improvement. Updated analyses pointed to a lower risk of death across Western and Asian patient subgroups, though the FDA did not find this sufficient to change its decision.
The players
Summit Therapeutics
Summit Therapeutics is a biopharmaceutical company developing ivonescimab, a investigational lung cancer therapy, and it has argued that longer follow-up supports the drug's benefit.
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is the federal agency responsible for reviewing and approving drugs sold in the United States.
The details
The FDA issued a complete response letter, the formal notice that an application cannot be approved in its current form. The company's late-stage study formed part of its marketing application, and the agency concluded that the progression-free survival benefit alone did not support a favorable benefit-risk profile.
Timeline
November 15, 2026: The FDA issued the complete response letter declining approval of ivonescimab.
Roadmap
The decision reflects the FDA's continued insistence that oncology drugs show a meaningful overall survival benefit, not only delayed tumor progression. It places Summit's application within a broader debate over how much weight progression-free survival should carry in lung cancer approvals.
Patients with progressed lung cancer cannot access ivonescimab through a U.S. approval for now, so current treatment options remain the relevant choice. Patients considering trials or other therapies should discuss the decision and its implications with their oncologist.
The takeaway
A drug can delay cancer progression yet still fall short of approval if it does not show a meaningful survival benefit. Readers following lung cancer treatments should watch whether longer follow-up changes the overall survival picture.
Further reading
Explore more Cancer coverage to see how regulators evaluate new treatments for the disease.










